FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
Welcome to our Elsevier’s Oncology Journal Network Highlights page
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report five-year outcomes…
In a clinical trial, rusfertide cut the number of phlebotomies people with polycythemia vera (PCV) needed from nine to less than one per year.
Vincent Law says researchers on the verge of huge discoveries in treating brain tumors
In this virtual tumor board episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion about the management of metastatic PD-L1 low NSCLC.
Investigators have explored whether bariatric surgery may be associated with a reduced risk of breast cancer in female patients with obesity and/or hyperinsulinemia at the…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.
Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being…